14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $14.58 $20.11 Thursday, 2nd May 2024 DNLI stock ended at $16.81. This is 4.02% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 6.41% from a day low at $15.92 to a day high of $16.94.
90 days $14.58 $23.52
52 weeks $14.58 $33.31

Historical Denali Therapeutics Inc. prices

Date Open High Low Close Volume
Feb 21, 2024 $16.38 $16.62 $16.11 $16.53 1 159 979
Feb 20, 2024 $16.56 $17.00 $16.21 $16.54 1 260 803
Feb 16, 2024 $17.78 $17.98 $16.39 $17.02 3 354 571
Feb 15, 2024 $18.16 $18.65 $18.15 $18.36 1 124 775
Feb 14, 2024 $17.50 $17.98 $17.05 $17.89 1 041 361
Feb 13, 2024 $17.48 $17.70 $16.81 $17.06 1 311 059
Feb 12, 2024 $18.11 $18.93 $18.07 $18.55 1 266 667
Feb 09, 2024 $17.37 $18.19 $17.13 $18.05 1 222 226
Feb 08, 2024 $17.02 $17.49 $16.96 $17.20 903 348
Feb 07, 2024 $16.60 $17.38 $16.20 $16.95 824 002
Feb 06, 2024 $15.79 $16.66 $15.62 $16.63 815 887
Feb 05, 2024 $15.68 $16.01 $15.52 $15.83 632 875
Feb 02, 2024 $16.00 $16.14 $15.54 $16.05 907 945
Feb 01, 2024 $16.16 $16.45 $15.79 $16.39 874 097
Jan 31, 2024 $16.60 $16.67 $15.90 $16.01 2 025 248
Jan 30, 2024 $17.31 $17.36 $16.68 $16.71 883 535
Jan 29, 2024 $17.01 $17.60 $16.51 $17.52 719 696
Jan 26, 2024 $17.39 $17.59 $16.84 $16.87 509 207
Jan 25, 2024 $17.30 $17.65 $17.05 $17.20 616 200
Jan 24, 2024 $17.29 $17.29 $16.80 $17.11 769 284
Jan 23, 2024 $17.84 $17.84 $16.90 $17.10 720 394
Jan 22, 2024 $17.29 $17.55 $17.00 $17.32 698 091
Jan 19, 2024 $16.65 $17.13 $16.26 $17.09 881 140
Jan 18, 2024 $17.22 $17.22 $16.56 $16.73 1 198 609
Jan 17, 2024 $18.03 $18.10 $17.02 $17.12 1 347 769
Click to get the best stock tips daily for free!

About Denali Therapeutics Inc.

Denali Therapeutics. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ... DNLI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT